Addex Therapeutics Ltd (ADXN)

Addex Therapeutics Ltd (ADXN) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $5.4M; returns 1 day +2.7%, 1 week +7.6%, 1 year -69.8%.

Addex Therapeutics Ltd (ADXN), founded in 2002 and based in Geneva, Switzerland, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule allosteric modulators, primarily for neurological disorders. Allosteric modulators are compounds that indirectly regulate a target protein's activity.

Groups ADXN belongs to

• Clinical Stage Biopharma
• Biotechnology
• Clinical Stage
• Neurological Disorders
• Neuroscience
• Biopharmaceutical
• Drug Discovery
• CNS Disorders
• Strategic Partnerships
• Life Sciences
• Healthcare Innovation

ADXN financial model: income statement, cash flow and balance sheet